key: cord-0899083-lyhd8nfy authors: Leiman, David A.; Maratt, Jennifer K.; Ketwaroo, Gyanprakash A. title: AGA Institute Quality Measure Development for the Diagnosis and Management of COVID-19 date: 2020-11-24 journal: Gastroenterology DOI: 10.1053/j.gastro.2020.11.039 sha: d318a3451a8632e51abb47a85c399ad0b6ae17e3 doc_id: 899083 cord_uid: lyhd8nfy nan This document presents the official recommendations of the American Gastroenterological Association (AGA) regarding quality measures related to the diagnosis and management of the novel coronavirus, SARS-CoV-2. The current report outlines the process by which the Quality Committee (QC) evaluates guidance statements published by the AGA's Clinical Guidelines Committee (CGC) to inform measure development. The recommendations discussed in this report relate to what remains an unprecedented event in contemporary history with unique challenges for CGC guidance-related measure development. The following recommendations were developed by the QC in consultation with the CGC. Their development was fully funded by the AGA Institute, with no additional outside funding. The novel coronavirus, SARS-CoV-2, was first described in December 2019 in patients in Wuhan, China who developed severe pneumonia, and was named coronavirus-19 disease (COVID-19) by the World Health Organization on February 11, 2020 1 . It was classified as a pandemic on March 11, 2020 2 and there have been 9,105,230 cases in the United States as of November 1, 2020 3 . It is readily transmitted via aerosols 4 . Since the first descriptions of the pulmonary complications, numerous extra-intestinal manifestations have been described as well as gastrointestinal (GI) symptoms that include abdominal pain, nausea, vomiting, and diarrhea in addition to elevated transaminases. The target entry receptor for SARS-CoV-2 is thought to be ACE2 (angiotensin converting enzyme II), which is expressed throughout the upper and lower gastrointestinal tract as well as hepatobiliary parenchyma. As a result, endoscopic GI procedures in particular are considered high-risk encounters. Although progress has been made in the treatment of COVID-19 infections, and early results appear promising regarding vaccine development, there remains no cure. Therefore, infection control and prevention remain paramount. The AGA recently published three guidance documents to assist in interpreting the available evidence regarding COVID-19, with the goals of summarizing data and providing evidence-based recommendations for 1) evaluation and management of Gl and liver manifestations of COVID-19; 2) risk of COVID-19 transmission during endoscopy with recommendations for personal protective equipment (PPE); and 3) the role of implementing a SARS-CoV2 pretesting strategy prior to endoscopy [5] [6] [7] . The aggregate recommendation statements from these documents, exclusive of good practice statements, were evaluated for development as potential quality measures. Best practice statements which had their certainty assessed using a GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework were also evaluated as they pertained to recommendations for the consultative management of patients with COVID-19. J o u r n a l P r e -p r o o f A standardized process first implemented by the AGA in 2016 and outlined elsewhere 8 was utilized and concordant with previously employed methods for measure development 9 . Optimal understanding of this measure evaluation process will be enhanced by reading applicable portions of the topic guidelines. Briefly, the AGA Quality Committee follows a "guidelines to measures" protocol that is based on best practices outlined by the American Thoracic Society 10 . This process relies on the evaluation of forthcoming guideline recommendations to be reviewed by the QC. Recommendation statements are evaluated as potential measure concepts along several axes, including the strength of the recommendation and quality of the evidence as specified using GRADE methodology. Only those statements with strong recommendations based on high or moderate quality evidence are considered for further measure development, which includes an assessment of their potential utility for practicing gastroenterologists. This assessment involves QC subcommittee analysis of measure importance and, when appropriate, is followed by the formal creation of a measure prioritization brief outlining the decision rationale whereby topics are rated on their meaningfulness, potential magnitude of effect, quality gaps, feasibility, and applicability to gastroenterologists. High priority measure concepts subsequently undergo review and voting by the entire QC ahead of a 30-day public comment period prior to testing and formal adoption. Finally, measures that receive 60 percent or more of the full QC vote will be recommended for national implementation. Maintaining high-quality care is essential in a pandemic, not only to facilitate early diagnosis and detection, but also to halt its spread and optimize the use of limited resources. Developing measures to define high-quality care for use throughout the COVID-19 pandemic is challenging. Best practice recommendations are derived from a synthesis of the currently available data which, despite the abundance of interest in the topic, remains limited to-date. The dynamically changing prevalence rates and resource availability assessments continue to change and therefore the evidence regarding diagnosis and treatment is evolving, too. While working toward establishing a measurable standard for high-quality care for COVID-19, rapid dissemination of quality and peer-reviewed data such as that found in the recent guidance documents is paramount. Within this context, the QC does not currently recommend the development of any quality measure concepts for pre-procedure testing, completing endoscopic procedures, or for the consultative management of COVID-19 patients. Each recommendation statement was independently evaluated and an assessment was made as outlined in Table 1 . The most frequently identified limitation for further quality measure concept development is related to insufficient quality of available evidence and, relatedly, the strength of recommendations. For example, in the instance of performing lower GI J o u r n a l P r e -p r o o f procedures the use of N95 (or N99 or PAPR) masks is given a strong recommendation with low quality evidence. In other important instances, consequential data are lacking. In the instance of abnormal liver associated enzymes, there are not enough data that evaluating for alternative etiologies is a change from the current practice paradigm. Similarly, the recommendations to avoid pre-procedure testing in high prevalence areas may be in conflict with local or state-level recommendations with associated impacts on patient care. Another commonly identified factor limiting measure development is the lack of described quality gaps. Although these areas have not been broadly researched at this time, in the instance of performing any GI procedure in known or presumptively COVID-19 positive patients, it is unlikely anyone would be using surgical masks only as part of their PPE. Furthermore, reliable and specified means through which adherence can be calculated is critical for quality measures. As a result, although using two pairs of gloves as part of PPE is undoubtedly relevant, reliably evaluating and calculating measure satisfaction in this area would be challenging. Among other features particularly relevant to quality measure development is some performance stability over time, to both establish a benchmark and later against which comparisons can be made to measure practice. Necessarily, both the ongoing nature and expected impermanence of the current pandemic conditions likely limit the impact that quality measures would have as such a process is routinely expected to require several cycles of specification, testing, validation, and final approval for inclusion in quality payment programs. Given the novelty of COVID-19 and its profound effects on individual and public health, this year has seen the generation and publication of enormous volumes of data to guide clinical practice. The AGA's CGC has created a comprehensive and systematic evaluation of the available data to provide much needed guidance regarding preprocedure testing and peri-procedure safety as well as a context for interpreting gastrointestinal signs and symptoms related to this viral illness. Although rigorously evaluated, these guidance recommendations come with several important caveats, which is primarily related to quality of available evidence and its expected evolution. Together with their time-limited nature, these recommendations do not currently satisfy criteria for further development into quality measures. A critical initial step in evaluating guidance statements for measure concept development is assessing the quality of evidence and strength of recommendation. In the case of the COVID-related statements, few of the current statements achieved sufficient moderate to high quality evidence and sufficiently strong recommendations. Furthermore, the utility of any quality measure is dependent on the existence of gaps in care delivery. There are no data available to suggest any such gaps exist with respect to patient care. Finally, all practice patterns are dependent on local disease prevalence and acknowledged as such in the guidelines. The nature of the evolving pandemic necessarily implies dynamic responses and adaptations will be employed within that J o u r n a l P r e -p r o o f context. Together these realities limit the impact any such potential quality measure would have on practice. However, the QC strongly believes that the best practices outlined in the CGC guidelines should be followed whenever possible and appropriate. Importantly, the lack of specified quality measures does not indicate a lack of importance to quality improvement as it pertains to COVID care. The duration in which we will be practicing in the current state is unknown and therefore identifying opportunities for improvement is critical. Because of the increasing evidence base, establishing metrics for COVID-19 care is a first step. This will require more data and demonstrable gaps in the quality of care. There is also now robust evidence for disparities in outcomes between patient groups. It is highly likely care delivery gaps are also present, both among socioeconomically disadvantaged patient populations and across health systems; these are probably further pronounced during periods of healthcare strain such as occurs when communities experience outbreaks and "surges." Monitoring for variations in care delivery and outcomes in these situations will be important and are sources of particular interest for improvement. In contrast, generating a quality measure, including those on which clinicians can report as part of a systematic quality program such as the Merit-based Incentive Payment System (MIPS), relies on an extensive process of specification, testing, and formal programmatic submission 11 . This is therefore a more distal goal. There are already examples of projects that aimed to assess adherence and outcomes related to such pre-procedure testing 12 . More data in this regard will be increasingly valuable the longer the pandemic lasts. In conclusion, the current best practices, guidelines and recommendation statements from the AGA represent an essential synthesis of the available data regarding COVID-19 regarding pre-procedure testing and peri-procedure safety as well as context for interpreting gastrointestinal signs and symptoms related to this viral illness. The quality of the evidence, strength of recommendations, and lack of known quality gaps currently preclude the development of quality measures at this time. These, and other concepts, are expected to evolve with the pandemic and growing evidence base. The QC encourages practitioners to adhere to these recommendations when appropriate and feasible and track their impact through active engagement in quality improvement. With additional data, future quality concepts can be re-evaluated for formal quality measure development. Additional data are needed to assess potential benefits and harms to such an approach. In outpatients with new onset of diarrhea, (i) ascertain information about high risk contact exposure (ii) obtain a detailed history of symptoms associated with COVID-19, including fever, cough, shortness of breath, chills, muscle pain, headache, sore throat, or new loss of taste or smell (iii) obtain a thorough history for other GI symptoms, including nausea, vomiting, and abdominal pain. Obtaining a detailed history of GI symptoms and non-GI symptoms is essential to evaluating all patients during the pandemic and expected as part of routine gastrointestinal care which may limit impact of this recommendation. In outpatients with new onset GI symptoms (e.g., nausea, vomiting, abdominal pain, diarrhea) monitor for symptoms associated with COVID-19 as GI symptoms may precede COVID-related symptoms by a few days. In a high COVID-19 prevalence setting, COVID-19 testing should be considered. No measure concept to develop No demonstrated or suspected quality gap and uncertain magnitude of effect. The reported prevalence continue to vary, with different thresholds for high rates, indicating a broad presentation, and often lack thereof, of GI symptoms. In hospitalized patients with suspected or known COVID-19, obtain a thorough history of GI symptoms (nausea, vomiting, abdominal pain, diarrhea) including onset, characteristics, duration, and severity. No measure concept to develop No demonstrated or suspected quality gap and uncertain magnitude of effect. The majority of studies evaluated of GI symptoms in COVID-19 focused on hospitalized patients, in whom a direct association with COVID-19, cannot be confirmed. Further studies are warranted to determine the characteristics, including onset and duration, of Clinical features of patients infected with 2019 novel coronavirus in Wuhan World Health Organization AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19 AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy Translating Best Practices To Meaningful Quality Measures: From Measure Conceptualization to Implementation Development of Quality Measures for Acute Pancreatitis: A Model for Hospital-Based Measures in Gastroenterology An official American thoracic society workshop report: developing performance measures from clinical practice guidelines Updates to Medicare's Quality Payment Program That May Impact You Yield and Implications of Pre-Procedural COVID-19 PCR Testing on Routine Endoscopic Practice GI symptoms in relation to other COVID-19 symptoms, in hospitalized and outpatient settings, in order to develop measures based on high quality evidence. There is presently inadequate evidence to support stool testing for diagnosis or monitoring of COVID-19 as part of routine clinical practice. Personal protective equipment: PPE *These recommendations assume the absence of widespread reliable rapid testing for the diagnosis of COVID-19 infection or immunity ΒΆ These recommendations assume that all patients are systematically screened for COVID-19 symptoms using the CDC screening checklist and are required to wear masks while in the endoscopy unit.